ICU sedation, delirium & recovery

Pharmacological agents for procedural sedation and analgesia in the emergency department and intensive care unit: a systematic review and network meta-analysis of randomised trials

Br J AnaesthPublished Systematic review and network meta-analysis of randomised trials

Authors' conclusion

When considering procedural sedation and analgesia in the ED and ICU, compared with midazolam-opioids, sedation recovery time is shorter with propofol, patient satisfaction is better with ketamine-propofol, and respiratory adverse events are less common with ketamine.

Study context

Population
Adults and children >30 days of age requiring emergent procedures with procedural sedation and analgesia (PSA) in the emergency department (ED) or ICU
Participants
8,105 adults · 82 RCTs
Comparison
i.v. PSA agents vs midazolam-opioids
Methodological detailsfrequentist random-effects model, Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) certainty rating
  • Frequentist random-effects model
  • GRADE certainty rating

Further pooled results

OutcomeMean difference (min) (95% CI)
Sedation recovery timePropofol vs Midazolam-opioids · fewer minutes; high certainty16.3 (8.4–24.3)
OutcomeMean difference (points) (95% CI)
Patient satisfactionKetamine-propofol vs Midazolam-opioids · better; high certainty1.5 (0.3–2.6)

Safety

OutcomeRR (95% CI)
Respiratory AEsKetamine vs Midazolam-opioids · high certainty0.55 (0.32–0.96)
Gastrointestinal AEsKetamine-midazolam vs Midazolam-opioids · high certainty3.08 (1.15–8.27)
Neurological AEsKetamine-propofol vs Midazolam-opioids · high certainty3.68 (1.08–12.53)

Original publication

Pharmacological agents for procedural sedation and analgesia in the emergency department and intensive care unit: a systematic review and network meta-analysis of randomised trials. Br J Anaesth. Published 6 January 2024. doi:10.1016/j.bja.2023.11.050

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.